**Supplemental Digital Content 3- Table 3.** The number and incidence of predominant non-PCV13 serotypes associated with IPD from children < 16 years of age, 2007-08 to 2017-18

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Type | 2007-08 | 2008-09 | 2009-10 | 2010-11 | 2011-12 | 2012-13 | 2013-14 | 2014-15 | 2015-16 | 2016-17 | 2017-18 | IRR | 95%CI | P value |
| n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR | n | IR |
| 8 | 2 | 0.21 | 1 | 0.10 | 1 | 0.10 | 1 | 0.10 | 2 | 0.19 | 1 | 0.10 | 0 | 0.00 | 1 | 0.09 | 1 | 0.09 | 1 | 0.09 | 2 | 0.19 | 0.88 | 0.12-6.25 | 0.8987 |
| 21 | 1 | 0.11 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.19 | 0 | 0.00 | - | 0.01-7.20 | 0.4528 |
| 38 | 2 | 0.21 | 0 | 0.00 | 0 | 0.00 | 2 | 0.20 | 2 | 0.19 | 0 | 0.00 | 1 | 0.09 | 1 | 0.09 | 3 | 0.28 | 1 | 0.09 | 0 | 0.00 | - | 0.01-3.67 | 0.2623 |
| 10A | 0 | 0.00 | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 3 | 0.29 | 3 | 0.28 | 0 | 0.00 | 0 | 0.00 | 1 | 0.09 | 3 | 0.28 | - | 0.32-119.33 | 0.229 |
| 11A | 1 | 0.11 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 3 | 0.29 | 2 | 0.19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.09 | 0.88 | 0.06-14.08 | 0.9283 |
| 12A | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 3 | 0.28 | 0 | 0.00 | 0 | 0.00 | - | 0.02-44.38 | 0.9493 |
| 12F | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 1 | 0.09 | 3 | 0.28 | 1 | 0.09 | 5 | 0.47 | 3 | 0.28 | - | 0.32-119.33 | 0.229 |
| 15A | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.10 | 1 | 0.10 | 1 | 0.09 | 1 | 0.09 | 2 | 0.19 | 2 | 0.19 | 1 | 0.09 | - | 0.11-64.88 | 0.552 |
| 15B/C | 0 | 0.00 | 0 | 0.00 | 2 | 0.20 | 1 | 0.10 | 1 | 0.10 | 0 | 0.00 | 5 | 0.47 | 3 | 0.28 | 3 | 0.28 | 2 | 0.19 | 2 | 0.19 | - | 0.21-91.70 | 0.3387 |
| 22F | 1 | 0.11 | 0 | 0.00 | 1 | 0.10 | 2 | 0.20 | 1 | 0.10 | 3 | 0.29 | 3 | 0.28 | 1 | 0.09 | 0 | 0.00 | 1 | 0.09 | 3 | 0.28 | 2.64 | 0.27-25.39 | 0.4002 |
| 23A | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.19 | 0 | 0.00 | 2 | 0.19 | 0 | 0.00 | 1 | 0.09 | - | 0.11-64.84 | 0.552 |
| 23B | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.19 | 3 | 0.28 | 1 | 0.09 | 6 | 0.56 | 3 | 0.28 | 4 | 0.37 | - | 0.43-147.19 | 0.165 |
| 24F | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 4 | 0.38 | 2 | 0.19 | 5 | 0.47 | 1 | 0.09 | - | 0.11-64.84 | 0.552 |
| 33F | 1 | 0.11 | 1 | 0.10 | 1 | 0.10 | 1 | 0.10 | 1 | 0.10 | 1 | 0.10 | 0 | 0.00 | 2 | 0.19 | 5 | 0.47 | 1 | 0.09 | 1 | 0.09 | 0.88 | 0.06-14.08 | 0.9283 |
| 35B | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 2 | 0.19 | 2 | 0.19 | 1 | 0.09 | 1 | 0.09 | - | 0.11-64.84 | 0.552 |
| 35F | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.19 | 0 | 0.00 | 1 | 0.09 | 3 | 0.28 | 0 | 0.00 | - | 0.02-44.38 | 0.9493 |
| 6C | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.20 | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | - | 0.02-44.38 | 0.9493 |
| 9N | 1 | 0.11 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 1 | 0.09 | 0 | 0.00 | 1 | 0.09 | 3 | 0.28 | 2.64 | 0.27-25.39 | 0.4002 |
| others\* | 0 | 0.00 | 1 | 0.10 | 0 | 0.00 | 0 | 0.00 | 3 | 0.29 | 0 | 0.00 | 0  | 0.00 | 3 | 0.28 | 0 | 0.00 | 1 | 0.09 | 3 | 0.28 | 2.64 | 0.27-25.39 | 0.4002 |

IR denotes the incidence rate of typed isolates per 100,000 population per epidemiological year. n= number of isolates typed per epidemiological year.

Incidence Rate Ratio (IRR) denotes the ratio between the incidence rate of typed isolates in the epidemiological year 2017-18 comparison to the pre PCV-vaccine epidemiological year 2007-08. 95% CI denotes the 95% confidence interval of the IRR. others\* represents non-PCV13 serotypes that were typed in low numbers including 17F, 20, 24B, 34 (n=2 each over 11 years) and 7A and 29 (1 each).